Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength

Abstract

The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

1 .- 89 . (canceled) 
     
     
         90 . A method for treatment or prophylaxis of bleeding in a subject with subnormal clot strength and stability, the method comprising administration of an effective amount of an adrenergic receptor agonist to said subject. 
     
     
         91 . The method according to  claim 90 , wherein the adrenergic receptor agonist is adrenaline or noradrenaline. 
     
     
         92 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered in the range 0.1 to 100 microgram/kg. 
     
     
         93 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered in the range 0.1 microgram/kg/hour to 25 microgram/kg/hour. 
     
     
         94 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered in the range 0.1 microgram/kg/hour to 20 microgram/kg/hour. 
     
     
         95 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered in the range 1 microgram/kg/hour to 10 microgram/kg/hour. 
     
     
         96 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered systemically. 
     
     
         97 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered intravenously. 
     
     
         98 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered by intravenous infusion. 
     
     
         99 . The method according to  claim 90 , wherein the adrenergic receptor agonist is administered continuously. 
     
     
         100 . The method according to  claim 90 , wherein the administration results in a systemic concentration of the adrenergic receptor agonist. 
     
     
         101 . The method according to  claim 90 , wherein the subject is human. 
     
     
         102 . The method according to  claim 90 , wherein the subject is suffering from thrombocytopenia. 
     
     
         103 . The method according to  claim 102 , wherein the thrombocytopenia is caused by decreased bone marrow production of megakaryocytes. 
     
     
         104 . The method according to  claim 90 , wherein the bleeding in said subject is caused by a combination of coagulopathy and thrombocytopenia. 
     
     
         105 . The method according to  claim 90 , wherein the subnormal clot strength and stability in said subject is due to low platelet function. 
     
     
         106 . The method according to  claim 90 , wherein the subject is suffering from drug-induced thrombocytopenia. 
     
     
         107 . The method according to  claim 90 , wherein the subject is suffering from chemotherapy-induced thrombocytopenia. 
     
     
         108 . The method according to  claim 90 , wherein administration of the adrenergic receptor agonist increases clot strength and stability in said subject. 
     
     
         109 . A method for treatment or prophylaxis of bleeding in a subject suffering from thrombocytopenia, the method comprising administration of an effective amount of an adrenergic receptor agonist to said subject.